Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2004 2
2005 1
2007 3
2008 3
2009 2
2010 2
2011 5
2012 5
2013 3
2014 13
2015 17
2016 20
2017 13
2018 33
2019 42
2020 81
2021 64
2022 72
2023 69
2024 40

Text availability

Article attribute

Article type

Publication date

Search Results

436 results

Results by year

Filters applied: . Clear all
Page 1
Therapeutic Targeting of CDK12/CDK13 in Triple-Negative Breast Cancer.
Quereda V, Bayle S, Vena F, Frydman SM, Monastyrskyi A, Roush WR, Duckett DR. Quereda V, et al. Cancer Cell. 2019 Nov 11;36(5):545-558.e7. doi: 10.1016/j.ccell.2019.09.004. Epub 2019 Oct 24. Cancer Cell. 2019. PMID: 31668947 Free article.
Here we report the development of SR-4835, a highly selective dual inhibitor of CDK12 and CDK13, which disables triple-negative breast cancer (TNBC) cells. Mechanistically, inhibition or loss of CDK12/CDK13 triggers intronic polyadenylation site cleavage that …
Here we report the development of SR-4835, a highly selective dual inhibitor of CDK12 and CDK13, which disables triple-negative breas …
Targeting CDK12 for Cancer Therapy: Function, Mechanism, and Drug Discovery.
Liu H, Liu K, Dong Z. Liu H, et al. Cancer Res. 2021 Jan 1;81(1):18-26. doi: 10.1158/0008-5472.CAN-20-2245. Epub 2020 Sep 21. Cancer Res. 2021. PMID: 32958547 Review.
Cyclin-dependent kinase 12 (CDK12) is a member of the CDK family of proteins (CDK) and is critical for cancer development. ...However, there remains a lack of understanding regarding the role of CDK12 in carcinogenesis and cancer prevention. An exhaust …
Cyclin-dependent kinase 12 (CDK12) is a member of the CDK family of proteins (CDK) and is critical for cancer development. ... …
Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer.
Wu YM, Cieślik M, Lonigro RJ, Vats P, Reimers MA, Cao X, Ning Y, Wang L, Kunju LP, de Sarkar N, Heath EI, Chou J, Feng FY, Nelson PS, de Bono JS, Zou W, Montgomery B, Alva A; PCF/SU2C International Prostate Cancer Dream Team; Robinson DR, Chinnaiyan AM. Wu YM, et al. Cell. 2018 Jun 14;173(7):1770-1782.e14. doi: 10.1016/j.cell.2018.04.034. Cell. 2018. PMID: 29906450 Free PMC article.
Using integrative genomic analysis of 360 metastatic castration-resistant prostate cancer (mCRPC) samples, we identified a novel subtype of prostate cancer typified by biallelic loss of CDK12 that is mutually exclusive with tumors driven by DNA repair deficie …
Using integrative genomic analysis of 360 metastatic castration-resistant prostate cancer (mCRPC) samples, we identified a novel subt …
CDK12: a potential therapeutic target in cancer.
Emadi F, Teo T, Rahaman MH, Wang S. Emadi F, et al. Drug Discov Today. 2020 Dec;25(12):2257-2267. doi: 10.1016/j.drudis.2020.09.035. Epub 2020 Oct 7. Drug Discov Today. 2020. PMID: 33038524 Review.
Current CDK12 inhibitors are nonselective, which impedes the process of pharmacological target validation and drug development. Herein, we discuss the latest understanding of the biological roles of CDK12 in cancers and provide molecular analyses of CDK12 …
Current CDK12 inhibitors are nonselective, which impedes the process of pharmacological target validation and drug development. Herei …
Transcription-associated cyclin-dependent kinase 12 (CDK12) as a potential target for cancer therapy.
Wu W, Yu S, Yu X. Wu W, et al. Biochim Biophys Acta Rev Cancer. 2023 Jan;1878(1):188842. doi: 10.1016/j.bbcan.2022.188842. Epub 2022 Nov 29. Biochim Biophys Acta Rev Cancer. 2023. PMID: 36460141 Review.
A comprehensive understanding of CDK12 will tremendously facilitate the exploitation of novel tactics for the treatment and precaution of cancer. ...Herein, we summarize the newly comprehension of the biological functions of CDK12 with a focus on recently eme …
A comprehensive understanding of CDK12 will tremendously facilitate the exploitation of novel tactics for the treatment and precautio …
CDK12: A Potent Target and Biomarker for Human Cancer Therapy.
Liang S, Hu L, Wu Z, Chen Z, Liu S, Xu X, Qian A. Liang S, et al. Cells. 2020 Jun 18;9(6):1483. doi: 10.3390/cells9061483. Cells. 2020. PMID: 32570740 Free PMC article. Review.
Recently, increasing evidence demonstrates the important role of CDK12 in various human cancers, illustrating it as both a biomarker of cancer and a potential target for cancer therapy. Here, we summarize the current knowledge of CDK12, and revi …
Recently, increasing evidence demonstrates the important role of CDK12 in various human cancers, illustrating it as both a bio …
Targeting signaling pathways in prostate cancer: mechanisms and clinical trials.
He Y, Xu W, Xiao YT, Huang H, Gu D, Ren S. He Y, et al. Signal Transduct Target Ther. 2022 Jun 24;7(1):198. doi: 10.1038/s41392-022-01042-7. Signal Transduct Target Ther. 2022. PMID: 35750683 Free PMC article. Review.
Prostate cancer (PCa) affects millions of men globally. Due to advances in understanding genomic landscapes and biological functions, the treatment of PCa continues to improve. ...Advanced clinical studies with immune checkpoint inhibitors (ICIs) have shown limited benefit …
Prostate cancer (PCa) affects millions of men globally. Due to advances in understanding genomic landscapes and biological functions, …
CDK12: an emerging therapeutic target for cancer.
Lui GYL, Grandori C, Kemp CJ. Lui GYL, et al. J Clin Pathol. 2018 Nov;71(11):957-962. doi: 10.1136/jclinpath-2018-205356. Epub 2018 Aug 13. J Clin Pathol. 2018. PMID: 30104286 Free PMC article. Review.
Genomic alterations in CDK12 have been detected in oesophageal, stomach, breast, endometrial, uterine, ovarian, bladder, colorectal and pancreatic cancers, ranging from 5% to 15% of sequenced cases. ...Herein, we discuss the present literature on CDK12 in cel …
Genomic alterations in CDK12 have been detected in oesophageal, stomach, breast, endometrial, uterine, ovarian, bladder, colorectal a …
Inhibition of CDK12 elevates cancer cell dependence on P-TEFb by stimulation of RNA polymerase II pause release.
Wang Z, Himanen SV, Haikala HM, Friedel CC, Vihervaara A, Barborič M. Wang Z, et al. Nucleic Acids Res. 2023 Nov 10;51(20):10970-10991. doi: 10.1093/nar/gkad792. Nucleic Acids Res. 2023. PMID: 37811895 Free PMC article.
We show that selective targeting of CDK12 in colon cancer-derived cells activates P-TEFb via its release from the inhibitory 7SK snRNP. ...Amongst the induced genes are those stimulated by hallmark pathways in cancer, including p53 and NF-kappaB. Consequently …
We show that selective targeting of CDK12 in colon cancer-derived cells activates P-TEFb via its release from the inhibitory 7 …
CDK inhibitors in cancer therapy, an overview of recent development.
Zhang M, Zhang L, Hei R, Li X, Cai H, Wu X, Zheng Q, Cai C. Zhang M, et al. Am J Cancer Res. 2021 May 15;11(5):1913-1935. eCollection 2021. Am J Cancer Res. 2021. PMID: 34094661 Free PMC article. Review.
Dysregulated cell division, which leads to aberrant cell proliferation, is one of the key hallmarks of cancer. Therefore, therapeutic targets that block cell division would be effective for cancer treatment. ...These CDKIs include CDK4/6, CDK7, CDK9, and CDK12 …
Dysregulated cell division, which leads to aberrant cell proliferation, is one of the key hallmarks of cancer. Therefore, therapeutic …
436 results